20 research outputs found

    Highly uniform and low-loss passive silicon photonics devices using a 300mm CMOS platform

    Get PDF
    Using an advanced 300mm CMOS-platform, we report record-low and highly-uniform propagation loss: 0.45 +/- 0.12dB/cm for wires, and 2dB/cm for slot waveguides. For WDM devices, we demonstrate channel variation(3-sigma) within-wafer and within-device of 6.1nm and 1.2nm respectively

    A European Television Fiction Renaissance. Premium Production Models and Transnational Circulation

    No full text
    This book maps the landscape of contemporary European premium television fiction, offering a detailed overview of both the changes in the digital production and distribution and the emergence of specific national and transnational case histories. Combining a media-production approach with a textual and audience analysis, the volume offers a complex, stratified, systemic view of ongoing aesthetic, sociocultural and industrial developments in contemporary European TV. With contributions from leading experts in the field, the book first offers an overview of the industrial, policy and cultural context for the renaissance of European television drama over the past decade, based on original comparative research. This research is then supported by case study chapters from the key contexts within which quality European television is being produced, offering a complex and complete picture of the industry\u2019s strengths and limitations, its traditions and trends, its constraints and future perspectives

    Dose-Finding Study of a CEA-Targeting Agent, SGM-101, for Intraoperative Fluorescence Imaging of Colorectal Cancer

    No full text
    Background: Carcinoembryonic antigen is overexpressed in colorectal cancer (CRC), making it an optimal target for fluorescence imaging. A phase I/II study was designed to determine the optimal imaging dose of SGM-101 for intraoperative fluorescence imaging of primary and recurrent CRC. Methods: Patients were included and received a single dose of SGM-101 at least 24 h before surgery. Patients who received routine anticancer therapy (i.e., radiotherapy or chemotherapy) also were eligible. A dedicated near-infrared imaging system was used for real-time fluorescence imaging during surgery. Safety assessments were performed and SGM-101 efficacy was evaluated per dose level to determine the most optimal imaging dose. Results: Thirty-seven patients with CRC were included in the analysis. Fluorescence was visible in all primary and recurrent tumors. In seven patients, no fluorescence was seen; all were confirmed as pathological complete responses after neoadjuvant therapy. Two tumors showed false-positive fluorescence. In the 37 patients, a total of 97 lesions were excised. The highest mean intraoperative tumor-to-background ratio (TBR) of 1.9 (p = 0.019) was seen in the 10-mg dose. This dose showed a sensitivity of 96%, specificity of 63%, and negative predictive value of 94%. Nine patients (24%) had a surgical plan alteration based on fluorescence, with additional malignant lesions detected in six patients. Conclusions: The optimal imaging dose was established at 10 mg 4 days before surgery. The results accentuate the potential of SGM-101 and designated a promising base for the multinational phase III study, which enrolled the first patients in June 2019
    corecore